HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Smadel, J. E. Search for Related Content PubMed Articles by Smadel, J. E.

Symposium on Immunization against Arbovirus Infections: Summary^*

First I wish to thank the participants for their excellent presentations.

It was suggested that the chairman provide a brief summary of the Symposium. I have chosen to do this in the form of a reply to a hypothetical question raised by a health officer and phrased as follows: "What new or improved immunoprophylactic procedures will be ready in the reasonably near future for my use in the prevention of arbovirus diseases of man?"

The aforementioned health officer should be encouraged by the progress being made toward the development of vaccines against several specific infections, and by the accumulation of basic information on approaches that might lead to induction of broad immunity against a wide spectrum of arboviruses. However, none of the vaccines or potential vaccines described today will be available as a commercially produced, licensed vaccine within a year.

The inactivated Rift Valley fever vaccine prepared by Dr. Randall and his associates from monkey-kidney tissue cultures, by techniques analogous to those developed for manufacturing safe Salk vaccine, is potent and safe in animals and man.

^* Presented at the annual meeting of the American Society of Tropical Medicine and Hygiene, Atlanta, Georgia, on November 2, 1962.